Breaking News, Collaborations & Alliances

Cullinan Oncology & MABD Enter Collaboration

To develop novel antibody therapeutics based on MABD's unique discovery platform.

Cullinan Oncology and MAB Discovery GmbH (MABD), announced the initiation of a collaboration to develop novel antibody therapeutics based on MABD’s unique discovery platform.   “We are excited to enter into this collaboration as the MABD development engine provides us with access to highly differentiated monoclonal antibodies” said Patrick Baeuerle, Cullinan’s chief scientific officer, Biologics. “Our first program is a novel agonistic antibody that has the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters